Skip to Content

Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$517.00QhznXnptpcql

Merck Looks Well Positioned With Keytruda, Gardasil, and a Strengthening Pipeline

Business Strategy and Outlook

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the Organon business in June 2021, the remaining portfolio at Merck holds a higher percentage of drugs with strong patent protection. On the pipeline front, after several years of only moderate research and development productivity, Merck's drug development strategy is yielding important new drugs.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center